There were three big takeaways from yesterday’s White House “listening session” on PBMs: The White House wants the David vs Goliath narrative. Of the five non-government speakers, four represented pharmacies.

There are two ways of looking at the ruling against AstraZeneca in its IRA lawsuit. (If you want to catch up quick on the basics, Bloomberg Law has you covered.)

Look, there’s not much going on today, so I won’t waste your time with a lot of fluff.  In the absence of actual news, I’m paying close attention to potential

I mentioned yesterday that Merck had dropped its annual drug-price transparency report, warning that Merck’s numbers probably shouldn’t be extrapolated to the broader industry. After all, most companies don’t have

As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report

So PBM reform is dead, according to the political press covering the government funding negotiations. STAT confirmed that fact with 11 different people, which is a feat.  (Modern Healthcare, not

There’s a lot to go through today, but before I get started, I have a favor to ask: if you like what you’re reading, please forward it to a friend. 

Pretty much every page of the new IQVIA “Global Trends in R&D 2024” report is worth deep consideration. It is the definitive atlas of how and where biopharma is investing

I could try to summarize it, but you’re probably better off just clicking over the Adam Fein’s latest post at Drug Channels today. Adam take a deep dive into the

After a chill week, we’re back to drinking from the firehose. One of the larger, if not sufficiently heralded, wins for the patient advocacy community last year was the effort